PetMed Express (PETS): High-Risk Turnaround, Hidden Assets, Activism

PetMed Express (PETS) is a declining pet pharmacy and pet healthcare company. The current market valuation ignores several factors. Includes cash, real estate, prior acquisition interest, and signs of management’s turnaround efforts. Two prior acquisition bids were $4-4.25 per share. Yes, revenue is declining, and margins are decreasing. And the share price has fallen. Further, concerns have increased due to competition. The current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support. Although continued operating losses will reduce that support.

PETS lacks a permanent CEO. Or an interim CEO with experience in the pet pharmacy industry. Leadership stability is critical to turnarounds. An interim CEO makes for additional activist or new acquisition talks. Interim leadership might emphasize immediate value realization over long-term transformation.

Risks:

During the last 10Q, revenue fell 22.7%, and reorder sales fell 22.6%. Operating cash flow was –$23.7M. The $26.7M in goodwill was fully impaired due to lower forecasts and a declining market value. The $2.1M inventory write-down indicates operational errors. With interim leadership, it’s hard to turn a company around.

PETS is a high-risk turnaround. The business is shrinking. Although the balance sheet provides time. The stock trades at around $2.20, with a market cap of $46M and an enterprise value of $19.22M. Latest data show cash fell to about $26.9M from negative operational cash flow. The prior YOY cash balance was 54.72M.

Additional risks include permanent customer losses to competitors such as Chewy and Amazon. And failure to successfully integrate PetCareRx, continued cash burn, lack of permanent leadership, margin pressure from pricing competition, and possible impairment of brand value

PETS is mostly an asset backed special situation.

Management initiatives include cost reductions, PetCareRx integration, autoship expansion, digital improvements, and veterinary offerings.

The market price ignores the values of owned assets. PETS has $26.9M in cash, $12.2M in inventory, $1.6M in accounts receivable, $27.6M in property and equipment, and $32.8M in shareholder equity. Liabilities consist of normal operating costs rather than debt obligations. And investors overlook asset values that exceed GAAP.

The company owns its 14.60-acre Delray Beach, Florida headquarters and distribution facility, along with 2 acres of excess land. Based on comparable South Florida industrial and commercial property values. The Delray property may be worth approximately $35M. Although the exact market value is uncertain. This creates potential upside with a sale-leaseback or renewed outside interest.

For the nine months ended December 31, 2025, PETS generated $136.2 million in sales. Reorder sales were $112.7 million, representing approximately 83% of total sales. New order sales were $18.6 million, while membership fees contributed $4.9 million. The revenue continues to come from existing and repeat customers.

Additional assets include the PetMeds brand and PetCareRx trade name. And internet domains, toll-free customer assets, and a $5.3M investment in Vetster. Additionally, management reduced costs and inventory by integrating PetCareRx. Digital operations are improving, and Telehealth is expanding. Inventory dropped from $16.2M to $12.2M. When an asset-heavy company trades below its estimated private value. Strategic outcomes, such as the sale of the company, increase.

SilverCape announced in December 2025 that it would take PETS private for $4.00 a share. SilverCape changed its 13G status to 13D, making it the biggest outside investor. SilverCape increased its ownership stake to 12.20% (2,579,696 shares). Management used a poison pill to prevent SilverCape from acquiring more than 13% of the outstanding shares.  Soon after, Cardone Ventures submitted a cash offer of 4.25. Cardone mentioned the value of the PETS brand. Including its customer relationships, pharmacy platform, and operating infrastructure. Other major investors have also acquired positions. Nina Capital owns about 8.8% of PETS and has added to its position through open-market purchases. Pinnacle Value Fund acquired a position in 2025 at $2.84 per share. As of February 2026, Diveroli Investment Group owned 391,757 shares, equal to roughly 1.83% of PETS.

There is also reason to believe that discussion may still be possible. SilverCape’s proposal said it would “engage constructively” with the Board and management. Furthermore, neither management nor SilverCape publicly stated that negotiations or discussions had ended. Because SilverCape still owns over 12% of the company. Strategic discussions cannot be ruled out, although there is no public evidence that negotiations continue. We shouldn’t discount the possibility of PETS going private.

Sum of the parts valuation

Conservative valuation

With any hint of turnaround success, the valuation will increase substantially.

Supporting reasons for higher valuation: 

Reorder sales are 83% of total sales. PETS still owns customer relationships and brands. There is no debt burden, although its operating liabilities are large. And the Delray property may be worth over 40M, not $35M.